What this study is
In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival.
What's being tested
- Indocyanine green
Intervention · DRUG
- SPY-PHI
Intervention · DEVICE
Both interventions
The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
Study details
- Official title
- Evaluation of Intraoperative Tumor Margin Identification With Fluorescent Dye Imaging
- Sponsor
- Massachusetts General Hospital
- Conditions
- Benign Neoplasm · Malignant Neoplasm
- Enrolling
- 100 people
- Starts
- 2022-05-25
- Est. completion
- 2030-04-01
- Design
- Open-label, single group, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- All patients 18 years of age or older who present to Massachusetts General Hospital Department of Orthopaedic Surgery with a benign or malignant bone or soft tissue mass that is consented for surgery during the study period.
You can't join if
- Pregnant or nursing patients
- Patients with previously known anaphylaxis to IV contrast or iodine (other allergies may be considered on a case-by-case basis)
- Patients in renal failure who are not cleared for ICG administration by their primary physician or oncologist
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openMassachusetts General Hospital
Boston, Massachusetts, United States
- Santiago A Lozano-Calderon, MD, PhD · Contact617-643-4947slozanocalderon@mgh.harvard.edu
- Shreya Halur, BS · Contact617-726-4932shalur@mgh.harvard.edu
Recruiting
Study team
Sponsor
Massachusetts General Hospital
Study ID 2020P003481
Principal investigator
Santiago A Lozano-Calderon, MD, PhD
Massachusetts General Hospital
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.